ACQUITY UPLC Peptide CSH Columns
Reversed-Phase Peptide Columns
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Thank you for making these columns!
Analysis using UPLC and HPLC for potency and beyond use date tests
The column was very effective and give clear peak shapes with good accuracy for the tests being conducted.
Review Date: 2 Jun 2020 | Waters
ACQUITY UPLC CSH C18, 130Å Peptide Columns with a low-positive charged surface can be used with standard TFA-containing eluents or with a weaker acid modifier such as formic acid, eliminating the need to compromise between a reversed-phase eluent that delivers sharp peaks or one that minimizes reduction of the MS signal.
LC-UV-based Synthetic Peptide Impurity Tracking and Reporting with Compliant-Ready Empower 3 Software
In this application note, a UPLC-UV-based method is used for determining synthetic peptide product purity in accordance with the International Council for Harmonisation (ICH) and United States Pharmacopeia (USP) functionalities built into Empower 3 Chromatography Data Software.
Monitoring Synthetic Peptide Impurities with Improved Confidence in Analysis
This application note demonstrates how mass detection can be readily incorporated into an existing optical-based workflow for analysis of synthetic peptide impurities.
Monitoring Multiple Attributes in a Single Assay Using the ACQUITY QDa Detector
This application note demonstrates that product quality attributes can be identified, quantitated and reported from a single LC-MS acquisition using the ACQUITY QDa detector along with Empower software.
Selecting a Reversed-Phase Column for the Peptide Mapping Analysis of a Biotherapeutic Protein
A chromatographic peptide mapping method must provide adequate resolution and recovery of a broad set of peptides if it is to be used in the quality analysis of a biotherapeutic protein. In this application note, a range of reversed phase columns by Waters are analysed for their applicability to peptide mapping, demonstrating high peak capacity separations.
Improving Routine Analysis of Insulin Analogues using the ACQUITY QDa Detector
Many Insulin analogues have come to market with either faster response times or extended drug activity, these analogues differ from each other by a few amino acids. To ensure safety and efficacy, these analogues must undergo testing. This application note demonstrates the applicability of an LC-UV/MS workflow using the ACQUITY QDa Detector for purity, comparability and identity testing for insulin analyses.
TechTalk: Clear the noise for better chromatographic separation of GLP‑1 receptor agonists and insulin impurities
Friday, June 12 at 14:00 BST | 15:00 CEST | 09:00 EDT | 06:00 PDT
In the race to launch GLP‑1 generics and novel agonists, complex impurity analyses can directly impact your speed to market. Conventional columns often obscure peaks of critical impurities, leading to costly rework and increased regulatory scrutiny.
Join this SelectScience® TechTalk and discover new analytical tools designed to streamline your process and deliver reproducible, high-resolution separations of GLP‑1 receptor agonists (GLP-1 RAs) and insulin-related impurities – without relying on suppressive mobile‑phase additives. Michael Zagieboylo, Principal Product Manager at Waters Corporation, will share how improved resolution can accelerate method development, increase confidence in your results, and support faster time to market for your GLP-1 RA and insulin products.
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
TechTalk details
- Cost: Free to attend
- Location: Online
- Duration: 20 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
